Cambridge, UK, 18 October 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody® therapeutics, today announced the appointment of Theodora Harold as Chief Financial Officer.
Theodora gained significant experience as a Chief Financial Officer with early stage and growing companies in the biotech sector. She has a background in both industry and corporate finance with 20 years’ experience with private and listed biotech SMEs, including senior positions at PsiOxus Therapeutics, MISSION Therapeutics and Cytomyx Holdings plc.
Using its proprietary transgenic mouse and engineering expertise, Crescendo discovers and rapidly assembles 100% human VH building blocks into optimally configured mono- and multi-specific Humabody® therapeutics. The Company’s focus is on developing Humabody® Drug Conjugates (HDCs) and multi-specific immuno-oncology (IO) modulators. Both have the potential to unlock routes to novel biology and are therefore expected to establish a valuable new class of therapeutics. The Company aims to deliver on its goals through both in-house development and strategic partnerships.
Dr Peter Pack, CEO of Crescendo Biologics, said:
“Theo’s appointment as Crescendo’s new CFO places us in an excellent position to drive ahead with our ambitious plans to create a high value pipeline of differentiated Humabody® therapeutics for treating cancer indications with substantial unmet medical need. The experience that she brings to Crescendo strengthens the existing management team and is crucial in allowing us to continue building both strategic and financial value in the Company.
“We are now well set to capitalize on the momentum Crescendo has built which also resulted in our recently signed collaboration with Takeda.”
Theodora Harold, the new CFO, added:
“Crescendo is at a pivotal point following its recent partnering deal with Takeda and the Company is now moving to its next phase of development. I look forward to working with the management team to ensure the company achieves its full potential.”
Background on Theodora Harold
Theodora has significant experience as a Chief Financial Officer with early stage and growing companies in the biotech sector. Her background spans both industry and corporate finance with c.20 years of experience with private and listed biotech SMEs. Theodora has held various roles including at PsiOxus Therapeutics Ltd, MISSION Therapeutics Ltd, OrthoMimetics Ltd, and Cytomyx Holdings plc. Prior to this, Theodora qualified as a chartered accountant with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.
- ENDS -
Notes to Editors
About Crescendo Biologics Ltd
Crescendo Biologics is a biopharmaceutical company discovering and developing potent, highly differentiated mono- and multi-specific Humabody® therapeutics in oncology. The Company’s Humabody® therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH) with superior biophysical properties.
Crescendo is pursuing novel Humabody® -based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and HDCs (Humabody® Drug Conjugates), the next generation of ADCs.
Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Imperial Innovations and Takeda.
For more information, please visit the website: www.crescendobiologics.com
About Humabody® Therapeutics Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human VH domain building blocks (Humabody® VH) isolated using Crescendo’s proprietary transgenic mouse.
Compared with monoclonal antibodies, Humabodies offer a unique combination of potential benefits that results from their small size, cost-effective production and robust biophysical properties, allowing Crescendo to rapidly assemble and optimally configure an almost limitless range of Humabody formats.
Crescendo is developing a pipeline of novel, Humabody®-based therapeutics in oncology. HDCs (Humabody® Drug Conjugates) will deliver a superior therapeutic index to standard ADCs. Next-generation mono- and multi-specific Humabody® IO modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response, as well as enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment.
